Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 14, 2014; 20(22): 6869-6877
Published online Jun 14, 2014. doi: 10.3748/wjg.v20.i22.6869
Published online Jun 14, 2014. doi: 10.3748/wjg.v20.i22.6869
Evaluation of a novel choanoid fluidized bed bioreactor for future bioartificial livers
Cheng-Bo Yu, Xiao-Ping Pan, Liang Yu, Xiao-Peng Yu, Wei-Bo Du, Hong-Cui Cao, Jun Li, Ping Chen, Lan-Juan Li, States Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China
Xiao-Ping Pan, Wei-Bo Du, Lan-Juan Li, Hong-Cui Cao Jun Li, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou 310003, Zhejiang Province, China
Author contributions: Yu CB wrote the paper; Pan XP, Yu L, Yu XP, Du WB, Cao HC, Li J and Chen P critically reviewed the manuscript for important intellectual content; Li LJ supervised the study; all authors have read and approved the final manuscript for publication.
Supported by The Grants from the National Scientific and Technological Major Project of China, No. 2011ZX10004-901, No. 2013ZX10004904; the National Science and Technology Major Project, No. 2012ZX10002006
Correspondence to: Lan-Juan Li, MD, State Key Laboratory for Diagnosis and Treatment of Infectious Disease, First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou 310003, Zhejiang Province, China. ljli@zju.edu.cn
Telephone: +86-571-87236458 Fax: +86-571-87236459
Received: November 29, 2013
Revised: February 26, 2014
Accepted: March 6, 2014
Published online: June 14, 2014
Revised: February 26, 2014
Accepted: March 6, 2014
Published online: June 14, 2014
Core Tip
Core tip: We constructed a novel choanoid fluidized bed bioreactor (CFBB) and received a national invention patent. We evaluated the CFBB functionality based on microencapsulated immortalized human hepatocytes. For this purpose, we placed the cultured hepatocytes into the CFBB and circulated through Dulbecco’s Modified Eagle’s Medium media for 12 h and through exchanged plasma for 6 h. The bioartificial liver based on a fluidized-bed bioreactor with microencapsulated immortalized human hepatocytes appeared to be effective for improving severe hepatitis plasma parameters. The efficacy of this novel bioreactor is promising for the study of liver failure.